Skip to main content

Whole Genix receives the 2019 ‘Medicina Siglo XXI’ Award for Medical Innovation

By 30 de April de 2019No Comments
< Back to news
Nuria Nabau, co-founder and CKO of Whole Genix, and Cristian Tornador, co-founder and CEO of the company (Photo: El Suplemento)

Whole Genix receives the 2019 ‘Medicina Siglo XXI’ Award for Medical Innovation

The company Whole Genix, based in the Barcelona Science Park, received the 2019 'Medicina Siglo XXI' Award in the Medical Innovation category during the gala marking the II edition of these prizes, held on Friday in Hotel Arts in Barcelona. With these awards, the editorial group El Suplemento aims to value the professional, scientific and innovative talent of professionals who work for and for health in various specialties and from different Spanish cities.


Whole Genix (WG) was created in July 2014 in Barcelona and London by Nuria Nabau, doctor in molecular and cellular biology; Óscar González, doctor in theoretical chemistry; and Cristian Tornador, doctor in biomedicine. They took the decision to focus on specialisation in genetic analyses, using new next-generation genome sequencing (NGS) technologies and bioinformatics models aimed at translational medicine. In 2015, the Fundació Ritort joined the project.

The company is a front-runner in genetic-clinical consultancy for both physicians and hospitals in terms of the prevention, early diagnosis and efficient treatment of diseases, particularly in neoplastic processes. The WG team selects and interprets clinically significant genetic data, showing the patient’s genetic profile in the context of approved (FDA, EMA) personalised therapies or the final stages of clinical trials. Finally, experts in the field of clinical genetics and/or oncology compile the data into a single concise report, together with the associated clinical recommendations that are reported to the physicians.

For a specific diagnosis of the disease, an exhaustive analysis is performed on the data obtained from NGS through the use of bioinformatics tools and protocols that are internationally approved by genetic experts. WG also writes clinical reports based on genetic kits, whole exomes and whole genomes, and also has a liquid (blood) biopsy kit for the detection and follow-up of advanced cancer patients.

WG collaborates in R&D&i in cancer projects with national hospitals, the ICO (Catalan Institute of Oncology), the CNIO (National Centre for Oncological Research) and the AECC (Spanish Association Against Cancer). Its board of directors has also created the Fundació Teresa Moretó, which is a non-profit organisation that aims to raise money for biomedical research, and the companies BloodGenetics for the genetic analysis of blood-related diseases, and Genyx, focused on adapting people’s lifestyles, nutritional habits and physical exercise routines.